Prophylactic intravenous calcium therapy for exchange blood transfusion in the newborn

• Published in: Cochrane database of systematic reviews 2017-10, Vol.10 (10), p.CD011048
• Main Authors: Ogunlesi, Tinuade A, Lesi, Foluso Ea, Oduwole, Olabisi
• Format: Article
• Language: English
• Subjects: Administration, Intravenous; Apnea - etiology; Blood and Hematopoietic Disorders; Blood disorders; Calcium - administration & dosage; Calcium - adverse effects; Calcium - blood; Child health; Exchange Transfusion, Whole Blood - adverse effects; Heart Arrest - etiology; Humans; Hypocalcemia - etiology; Hypocalcemia - prevention & control; Hypoglycemia - etiology; Infant, Newborn; Neonatal care
• ISSN: 1469-493X
• DOI: 10.1002/14651858.CD011048.pub2

Exchange blood transfusion (EBT) is a form of whole blood transfusion in which the total blood volume is replaced within a few hours. In perinatal and neonatal medicine, EBT is most often used in the management of severe anaemia or severe hyperbilirubinaemia in the first week of life. Hypocalcaemia, one of the common morbidities associated with EBT, is thought to arise from the chelating effects of the citrate commonly used as an anticoagulant in the donor's blood. This disorder manifests with muscular and nervous irritability and cardiac arrhythmias. To determine whether the use of prophylactic calcium reduces the risk of hypocalcaemia-related morbidities and death among newborn infants receiving EBT. We used the standard search strategy of the Cochrane Neonatal Review group to search the Cochrane Central Register of Controlled Trials (CENTRAL 2016, Issue 5), MEDLINE via PubMed (1966 to 29 June 2016), Embase (1980 to 29 June 2016), and CINAHL (1982 to 29 June 2016). We also searched clinical trials databases, conference proceedings, and the reference lists of retrieved articles for randomised controlled trials and quasi-randomised trials. All randomised and quasi-randomised trials of prophylactic intravenous calcium in EBT for newborns. Two review authors independently assessed and extracted data on methods, participants, interventions, and outcomes (mean total and ionised serum calcium before and after EBT and the presence of adverse events such as hypoglycaemia, apnoea, cardiac arrest, and death immediately after EBT). We reported results as means difference (MD) with 95% confidence intervals (CI) for continuous outcomes and risk ratio (RR) and risk differences (RD) and 95% CIs for dichotomous outcomes. We assessed quality using the Cochrane 'Risk of bias' assessment tool and the GRADE system. We found only one quasi-randomised trial with 30 participants that met our inclusion criteria. In the small trial, total and ionised serum calcium levels were measured immediately before and immediately after EBT. All the participants were included in the final analysis and all the important outcomes were reported. Primary outcomesThere was one death in each group (RR 1.00, 95% CI 0.07 to 14.55; RD 0.00, 95% CI -0.18 to 0.18; participants = 30; studies = 1). The study did not report the presence of cardiac arrhythmias within one week of EBT and the number of infants with serum calcium levels (total less than 8 mg/dL (2 mmol/L) or ionised less than 4.4 mg/dL (1.1 m